An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients - the VOCOVID Study

Phase 2

Completed

• Conditions: Coronavirus; COVID-19; SARS-CoV-2; 10047438; 10038430

• Registration Number: NL-OMON55051
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

Subjects with a stable kidney transplant taking Tacrolimus and a confirmed
diagnosis of SARS-CoV-2 with mild-to-moderate symptoms

Exclusion Criteria

Severe symptoms resulting from SARS-CoV-2 infection requiring positive pressure
ventilation at baseline

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoint is the time to viral clearance of SARS-CoV-2 , as measured by<br /><br>first negative reverse transcription quantitative polymerase chain reaction<br /><br>(RT-qPCR) with a CT value of >37 over 56 days. </p><br>